The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases

NCT03711240 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: bevacizumab
DRUG: Oxaliplatin
DRUG: Irinotecan
DRUG: Leucovorin
DRUG: 5-FU

Sponsor

National Cheng-Kung University Hospital